Eyenovia Inc (NASDAQ: EYEN) reported Q2 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42).

Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer commented, “In the first half of 2018, we further validated our novel therapeutic platform with compelling IOP lowering and usability results from our EYN PG21 study and with the allowance of two new U.S. patents. As we continue to advance our late stage pipeline and, in particular, accelerate MicroPine for progressive myopia to address an estimated $5 billion potential U.S. market opportunity, we are excited to bring on board Michael Rowe as our VP of Marketing. In the near term, we look forward to leveraging his wealth of knowledge as we plan to submit two Investigational New Drug applications this year as well as the OTC registration for MicroTears for dry eye in 2019. We believe Michael’s commercial ophthalmology experience at both Aerie Pharmaceuticals, Inc. and Allergan plc will be a valuable asset in planning our strategic direction as we near commercialization.”

For earnings history and earnings-related data on Eyenovia Inc (EYEN) click here.